What is Aridis Pharmaceuticals?
Headquartered in Los Gatos, California, Aridis Pharmaceuticals operates as a late-stage biopharmaceutical entity dedicated to the discovery and development of targeted immunotherapy. By leveraging fully human monoclonal antibodies, the company aims to neutralize life-threatening infections that remain resistant to conventional treatments. Its core asset, AR-301, represents a significant advancement in clinical research, currently undergoing Phase III pivotal trials to combat lung infections caused by S. aureus alphatoxin. The company's focus on high-precision medical interventions positions it as a key player in the evolving landscape of infectious disease therapeutics, bridging the gap between laboratory innovation and clinical application.
How much funding has Aridis Pharmaceuticals raised?
Aridis Pharmaceuticals has raised a total of $6.8M across 3 funding rounds:
Debt
$3.5M
Debt
$3M
Debt
$350K
Debt (2014): $3.5M, investors not publicly disclosed
Debt (2015): $3M, investors not publicly disclosed
Debt (2020): $350K supported by PPP
Key Investors in Aridis Pharmaceuticals
PPP
Public-Private Partnership
Undisclosed Investors
Undisclosed Investors
What's next for Aridis Pharmaceuticals?
With the recent influx of capital, Aridis Pharmaceuticals is well-positioned to accelerate its late-stage clinical programs and navigate the complex regulatory pathways required for commercialization. The strategic focus will likely remain on the successful completion of Phase III trials for AR-301, which serves as a cornerstone for the company's long-term growth strategy. As the firm transitions toward potential market entry, the management team is expected to prioritize operational efficiency and the expansion of its monoclonal antibody pipeline. This phase of development is critical for establishing the company as a leader in the immunotherapy space, providing a robust foundation for future partnerships and sustained enterprise value.
See full Aridis Pharmaceuticals company page
